Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) saw some unusual options trading activity on Monday. Investors acquired 832 call options on the stock. This represents an increase of 605% compared to the typical volume of 118 call options.
Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) opened at $7.80 on Friday. Corbus Pharmaceuticals has a one year low of $5.30 and a one year high of $10.50. The company has a market cap of $428.01, a price-to-earnings ratio of -12.58 and a beta of 174.68.
Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. Corbus Pharmaceuticals had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. The business had revenue of $0.80 million during the quarter. research analysts expect that Corbus Pharmaceuticals will post -0.6 EPS for the current fiscal year.
Several equities research analysts have weighed in on the stock. BidaskClub upgraded shares of Corbus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Cantor Fitzgerald set a $28.00 price objective on shares of Corbus Pharmaceuticals and gave the stock an “overweight” rating in a research note on Thursday, December 14th. Noble Financial reiterated a “buy” rating on shares of Corbus Pharmaceuticals in a research note on Friday, December 15th. Finally, ValuEngine downgraded shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $25.00.
In other news, Director David P. Hochman bought 5,000 shares of the stock in a transaction on Wednesday, November 15th. The stock was bought at an average cost of $6.55 per share, for a total transaction of $32,750.00. Following the completion of the purchase, the director now directly owns 459,500 shares in the company, valued at $3,009,725. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David P. Hochman bought 10,000 shares of the stock in a transaction on Friday, November 10th. The stock was purchased at an average price of $7.08 per share, with a total value of $70,800.00. Following the completion of the purchase, the director now owns 459,500 shares of the company’s stock, valued at $3,253,260. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 25,336 shares of company stock valued at $175,632. 11.90% of the stock is owned by insiders.
Several large investors have recently bought and sold shares of CRBP. Credit Suisse AG acquired a new stake in shares of Corbus Pharmaceuticals during the first quarter worth $157,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of Corbus Pharmaceuticals during the second quarter worth $469,000. Rhumbline Advisers purchased a new position in shares of Corbus Pharmaceuticals during the second quarter worth $283,000. State of Wisconsin Investment Board purchased a new position in shares of Corbus Pharmaceuticals during the second quarter worth $202,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Corbus Pharmaceuticals by 548.3% during the second quarter. Bank of New York Mellon Corp now owns 136,812 shares of the biopharmaceutical company’s stock worth $862,000 after purchasing an additional 115,710 shares during the last quarter. Institutional investors and hedge funds own 27.84% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was first reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://transcriptdaily.com/2018/01/06/corbus-pharmaceuticals-target-of-unusually-large-options-trading-crbp.html.
About Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.